DRUG
enfuvirtide [Fuzeon]
90mg sc bid by Biojector 2000 NFID for 4 weeks
WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.
Status
Completed
Phase
Phase 4
Enrollment
58
Locations
17
Results
Not posted
Publications
1
Study summary
What the protocol is testing.
The purpose of this study is to evaluate the tolerability of a subcutaneous needle-free injection device used to administer Fuzeon, compared with the standard needle/syringe supplied with commercial Fuzeon. The anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.
Interventions
Treatment arms and agents.
DRUG
enfuvirtide [Fuzeon]
90mg sc bid by 27G1/2" needle/syringe for 4 weeks
Timeline
From registration to results.
First posted
Oct 6, 2005
Study start
Aug 2005
Primary completion
Jul 2006
Study completion
Jul 2006
Results posted
Not reported
Registry updated
Nov 3, 2015
Outcomes
What the study measures.
Primary outcomes
Composite endpoint (pain, induration, nodules/cysts).
Time frame · Throughout study
Secondary outcomes
Steady state C trough
Time frame · Weekly
Signs and symptoms associated with Fuzeon injections
Time frame · Throughout study
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * male or female patients, \>=18 years of age with HIV-1 infection; * previously treated with antiretroviral agents. Exclusion Criteria: * prior use of Fuzeon or T-1249; * inability to self-inject; * active, untreated opportunistic infection.
Study locations
17 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Facility not named
Long Beach, California, United States
Facility not named
Los Angeles, California, United States
Facility not named
Los Angeles, California, United States
Facility not named
Los Angeles, California, United States
Facility not named
Washington D.C., District of Columbia, United States
Facility not named
Fort Lauderdale, Florida, United States
Facility not named
South Miami, Florida, United States
Facility not named
Atlanta, Georgia, United States
Facility not named
Chicago, Illinois, United States
Facility not named
Chicago, Illinois, United States
Facility not named
Boston, Massachusetts, United States
Facility not named
Detroit, Michigan, United States
Facility not named
St Louis, Missouri, United States
Facility not named
Winston-Salem, North Carolina, United States
Facility not named
Dallas, Texas, United States
Facility not named
Houston, Texas, United States
Facility not named
Annandale, Virginia, United States
Publications
Results and literature.
Related trials
More studies on Enfuvirtide.
NCT IDStudyPhase / statusEnrollmentUpdated
Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)
French National Agency for Research on AIDS and Viral Hepatitis · HIV Infections · AIDS
Phase 3
Completed
195
2026-04
Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load
French National Agency for Research on AIDS and Viral Hepatitis · HIV Infections
Phase 3
Completed
170
2026-04
Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients
ANRS, Emerging Infectious Diseases · HIV Infection · Liver Failure
Phase 1 / Phase 2
Completed
14
2026-04
Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)
French National Agency for Research on AIDS and Viral Hepatitis · Leukoencephalopathy, Progressive Multifocal · HIV Infections
Phase 2
Completed
30
2026-04
Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy
University Hospital, Tours · HIV
Phase 3
Completed
224
2025-12
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen
Gilead Sciences · HIV-1-infection
Phase 2 / Phase 3
Active, not recruiting
689
2025-10
Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · HIV
Early Phase 1
Completed
11
2021-11
Optimizing Treatment for Treatment-Experienced, HIV-Infected People
National Institute of Allergy and Infectious Diseases (NIAID) · HIV Infections
Phase 3
Completed
517
2021-11
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.